Tau Protein, Aβ42 and S-100B Protein in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Dementia and Geriatric Cognitive Disorders

• Publication date

  2005-02-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1159/000083178
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies

  2004cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Insulin increases CSF Aβ42 levels in normal older adults

  2003cited by this paper
• Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum

  2003cited by this paper
• Diagnostic problems during late course in Creutzfeldt-Jakob disease

  2003cited by this paper
• Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

  2003cited by this paper
• Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.

  2003cited by this paper
• Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

  2003cited by this paper
• Aβ peptide1–42, Tau protein and S-100B protein level in cerebrospinal fluid of three patients with primary progressive aphasia

  2002cited by this paper
• Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children.

  2002cited by this paper
• Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease

  2002cited by this paper
• Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

  2001cited by this paper
• Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease.

  2001cited by this paper
• Homocarnosine and seizure control in juvenile myoclonic epilepsy and complex partial seizures

  2001cited by this paper
• CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies

  2001cited by this paper
• Developmental apraxia arising from neonatal brachial plexus palsy

  2000cited by this paper
• CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

  2000cited by this paper
• Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias.

  1999cited by this paper
• Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF

  1999cited by this paper
• Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.

  1998cited by this paper
• Cerebrospinal fluid levels of Aβ42 and tau: potential markers of Alzheimer’s disease

  1998cited by this paper
• Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.

  1997cited by this paper
• Increased S100β in the cerebrospinal fluid of patients with frontotemporal dementia

  1997cited by this paper
• Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice

  1997cited by this paper
• Effect of Genetic Risk Factors and Disease Progression on the Cerebrospinal Fluid Tau Levels in Alzheimer's Disease

  1997cited by this paper
• Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

  1997cited by this paper
• Criteria for Alzheimer's Disease and the Nosology of Dementia with Lewy Bodies

  1997cited by this paper
• S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

  1997cited by this paper
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB)

  1996cited by this paper
• Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease

  1995cited by this paper
• Apolipoprotein E gene in diffuse Lewy body disease with or without co-existing Alzheimer's disease.

  1994cited by this paper
• Neuroleptic sensitivity in patients with senile dementia of Lewy body type.

  1992cited by this paper
• The S-100 protein in cerebrospinal fluid: a simple ELISA method.

  1989cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Application of peptide biomarkers in life analysis based on liquid chromatography–mass spectrometry technology

  2022cites this paper
• The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy "in Vivo" in the Differential Diagnosis of Alzheimer's Dementia.

  2019cites this paper
• Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

  2019cites this paper
• Alpha-synuclein in cerebrospinal fluid

  2017cites this paper
• Diagnostic Validity Comparison Between Criteria Based on CSF Alzheimer’s Disease Biomarkers

  2017cites this paper
• Alzheimer’s Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate

  2017cites this paper
• The underexplored question of β-amyloid monomers.

  2017cites this paper
• CSF biomarkers in neurodegenerative and vascular dementias.

  2016cites this paper
• Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders

  2016influential citation
• A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid

  2016cites this paper
• The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer’s Disease: Shortcomings in Prodromal Diagnosis

  2016cites this paper
• Amyloid-β as a biomarker for Alzheimer’s disease: quantification methods in body fluids

  2015cites this paper
• How many biomarkers to discriminate neurodegenerative dementia?

  2015cites this paper
• Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders

  2015cites this paper
• Serum peptides as candidate biomarkers for dementia with Lewy bodies

  2015cites this paper
• Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies

  2015cites this paper
• Liquormarker in der Diagnostik bei Patienten mit Morbus Parkinson, Parkinson-Demenz-Komplex und

  2015cites this paper
• Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias

  2014cites this paper
• Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

  2014cites this paper
• What can biomarkers tell us about cognition in Parkinson's disease?

  2014cites this paper
• Biomarkers in biological fluids for dementia with

  2014cites this paper
• Biomarkers in biological fluids for dementia with Lewy bodies

  2014cites this paper
• Chapter 86 – Parkinson’s Disease

  2013cites this paper
• Evaluation of annexin A5 as a biomarker for Alzheimer's disease and dementia with lewy bodies

  2013cites this paper
• CSF levels of the neuronal injury biomarker visinin‐like protein‐1 in Alzheimer's disease and dementia with Lewy bodies

  2013cites this paper
• Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue.

  2013cites this paper
• Demência com Corpos de Lewy Aplicabilidade dos critérios de diagnóstico

  2013cites this paper
• Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort

  2012cites this paper
• Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

  2012cites this paper
• Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

  2012cites this paper
• CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD

  2012cites this paper
• S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway

  2012cites this paper
• Neurochemical biomarkers in Alzheimer’s disease and related disorders

  2012cites this paper
• The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging

  2012cites this paper
• Biomarkers in dementia with Lewy bodies: a review

  2012cites this paper
• Biomarkers in patients with idiopathic normal pressure hydrocephalus

  2012cites this paper
• Cognitive and Behavioral Neurology

  2012cites this paper
• Advances in Alzheimer’s Disease Management

  2012cites this paper
• Diagnosis of Alzheimer’s disease

  2012cites this paper
• Preclinical AD Workgroup staging: pathological correlates and potential challenges.

  2012cites this paper
• The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia

  2011cites this paper
• The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

  2011cites this paper
• S100B protein in neurodegenerative disorders

  2011cites this paper
• Disease specific cerebrospinal fluid investigations

  2011cites this paper
• CSF α-synuclein, tau, and amyloid β in Parkinson's disease – Authors' reply

  2011cites this paper
• Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40ox% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia

  2010cites this paper
• Biomarkers for Cognitive Impairment in Parkinson Disease

  2010cites this paper
• Differential Diagnosis of Rapid Progressive Dementia

  2010cites this paper
• Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies.

  2010cites this paper
• Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies.

  2010cites this paper
• Common, but Often Misdiagnosed Conditions

  2010cites this paper
• Biological Markers and Alzheimer Disease: A Canadian Perspective

  2010cites this paper
• Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

  2010cites this paper
• Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions.

  2010cites this paper
• CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.

  2009cites this paper
• Immuno‐MALDI‐TOF MS: New perspectives for clinical applications of mass spectrometry

  2009cites this paper
• Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid.

  2009cites this paper
• Cerebral white matter changes : Differentiating vascular and degenerative cognitive impairment

  2009cites this paper
• EFNS guidelines on disease‐specific CSF investigations

  2009cites this paper
• Cerebrospinal Fluid Total Tau Is Associated with Shorter Survival in Dementia with Lewy Bodies

  2009cites this paper
• Neurochemical biomarkers in the differential diagnosis of movement disorders

  2009cites this paper
• Increased frequency of positive family history of dementia in sporadic CJD.

  2009cites this paper
• Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration.

  2008cites this paper
• Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.

  2008cites this paper
• Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.

  2008cites this paper
• Tau as a biomarker of neurodegenerative diseases.

  2008cites this paper
• Early Discriminatory Diagnosis of Dementia with Lewy Bodies

  2008cites this paper
• Serum Heart-Type Fatty Acid-Binding Protein and Cerebrospinal Fluid Tau: Marker Candidates for Dementia with Lewy Bodies

  2007cites this paper
• Blood‐based neurochemical diagnosis of vascular dementia: a pilot study

  2007cites this paper
• Pharmacotherapy, clinical pharmacology and biomarker research in geriatric patients

  2007cites this paper
• ALZHEIMER'S DISEASE AND DEMENTIA WITH LEWY BODIES: SPECIAL FOCUS ON THE ROLE OF SERPINS

  2007cites this paper
• Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias

  2007cites this paper
• The role of biologic markers in the diagnosis of Alzheimer's disease

  2007cites this paper
• Reduced CSF carboxyterminally truncated Aβ peptides in frontotemporal lobe degenerations

  2007cites this paper
• Associations between white matter lesions, cerebrovascular risk factors, and low CSF Aβ42

  2006cites this paper
• Total tau protein, phosphorylated tau (181p) protein, β-amyloid1–42, and β-amyloid1–40 in cerebrospinal fluid of patients with dementia with Lewy bodies

  2006cites this paper
• CSF amyloid-b-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

  2006cites this paper
• CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

  2006cites this paper
• Biomarkers in chronic adult hydrocephalus

  2006cites this paper
• Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies

  2006cites this paper
• Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease Dementia

  2006cites this paper
• Diagnostik und Therapie von Parkinson-Demenz in der klinischen Praxis

  2006cites this paper
• CSF diagnosis of Alzheimer’s disease and dementia with Lewy bodies

  2006influential citation